| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Taro Kishi, Toshikazu Ikuta, Yuki Matsuda, Kenji Sakuma, Nakao Iwat. Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis. Psychopharmacology. vol 237. issue 5. 2020-09-15. PMID:32002559. |
aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis. |
2020-09-15 |
2023-08-13 |
Not clear |
| Peter J Weiden, Amy Claxton, Jelena Kunovac, David P Walling, Yangchun Du, Baiyun Yao, Sergey Yagoda, Ilda Bidollari, Elizabeth Keane, Ethan Cas. Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study. The Journal of clinical psychiatry. vol 81. issue 3. 2020-09-14. PMID:32433835. |
efficacy and safety of a 2-month formulation of aripiprazole lauroxil with 1-day initiation in patients hospitalized for acute schizophrenia transitioned to outpatient care: phase 3, randomized, double-blind, active-control alpine study. |
2020-09-14 |
2023-08-13 |
Not clear |
| Peter J Weiden, Amy Claxton, Jelena Kunovac, David P Walling, Yangchun Du, Baiyun Yao, Sergey Yagoda, Ilda Bidollari, Elizabeth Keane, Ethan Cas. Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study. The Journal of clinical psychiatry. vol 81. issue 3. 2020-09-14. PMID:32433835. |
evaluate efficacy and safety of a 2-month formulation of aripiprazole lauroxil (al) with 1-day initiation during hospitalization for acute exacerbation of schizophrenia followed by transition to outpatient care. |
2020-09-14 |
2023-08-13 |
Not clear |
| Peter J Weiden, Yangchun Du, Chih-Chin Liu, Arielle D Stanfor. Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period. CNS spectrums. vol 24. issue 4. 2020-08-19. PMID:29941057. |
switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period. |
2020-08-19 |
2023-08-13 |
Not clear |
| Henry A Nasrallah, Ralph Aquila, Yangchun Du, Arielle D Stanford, Amy Claxton, Peter J Weide. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. CNS spectrums. vol 24. issue 4. 2020-08-19. PMID:30109845. |
long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. |
2020-08-19 |
2023-08-13 |
Not clear |
| Henry A Nasrallah, Ralph Aquila, Yangchun Du, Arielle D Stanford, Amy Claxton, Peter J Weide. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. CNS spectrums. vol 24. issue 4. 2020-08-19. PMID:30109845. |
safety and tolerability of long-term treatment with the long-acting antipsychotic aripiprazole lauroxil (al) were evaluated in patients with schizophrenia. |
2020-08-19 |
2023-08-13 |
Not clear |
| Zhang Cheng, Yanbo Yuan, Xue Han, Lei Yang, Shangli Cai, Fude Yang, Zheng Lu, Chuanyue Wang, Hong Deng, Jingping Zhao, Yutao Xiang, Christoph U Correll, Xin Y. An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. Journal of psychopharmacology (Oxford, England). vol 33. issue 10. 2020-08-17. PMID:31487208. |
an open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: eight-week outcomes. |
2020-08-17 |
2023-08-13 |
Not clear |
| Zhang Cheng, Yanbo Yuan, Xue Han, Lei Yang, Shangli Cai, Fude Yang, Zheng Lu, Chuanyue Wang, Hong Deng, Jingping Zhao, Yutao Xiang, Christoph U Correll, Xin Y. An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. Journal of psychopharmacology (Oxford, England). vol 33. issue 10. 2020-08-17. PMID:31487208. |
this study aimed to investigate the efficacy and tolerability of aripiprazole, olanzapine and risperidone in first-episode schizophrenia (fes). |
2020-08-17 |
2023-08-13 |
Not clear |
| Tanja Veselinović, Martin Scharpenberg, Martin Heinze, Joachim Cordes, Bernd Mühlbauer, Georg Juckel, Ute Habel, Eckart Rüther, Jürgen Timm, Gerhard Gründe. Disparate effects of first and second generation antipsychotics on cognition in schizophrenia - Findings from the randomized NeSSy trial. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 29. issue 6. 2020-08-07. PMID:30981585. |
the aim of our multi-center, randomized, double-blind "neuroleptic strategy study" (nessy) was to compare the effectiveness of selected antipsychotics, conventionally classified as second- (sgas) (haloperidol, flupentixol) and first generation antipsychotics (fgas) (aripiprazole, olanzapine, quetiapine), on quality of life in schizophrenia. |
2020-08-07 |
2023-08-13 |
Not clear |
| Brian J Miller, Amy Claxton, Yangchun Du, Peter J Weiden, Steven G Potki. Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study. Schizophrenia research. vol 208. 2020-08-03. PMID:30745067. |
switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: a 6-month, prospective, open-label study. |
2020-08-03 |
2023-08-13 |
Not clear |
| Sarah Farwick, Magali B Hickey, Gwen Jacobs, Sejal P Faldu, Jennifer Vandiver, Peter J Weide. Best Practices for Aripiprazole Lauroxil Administration: From Formulation Development to Injection Technique. Journal of psychiatric practice. vol 25. issue 2. 2020-06-19. PMID:30849056. |
this article reviews the relationship between formulation technology and clinical practices for lais, with a focus on aripiprazole lauroxil, a long-acting atypical antipsychotic indicated for the treatment of schizophrenia. |
2020-06-19 |
2023-08-13 |
Not clear |
| Xavier Boland, Preeti Chhabr. Dramatic Weight Loss Following Addition of Aripiprazole to Olanzapine in a Patient With Treatment-resistant Schizophrenia: A Case Report. Journal of psychiatric practice. vol 25. issue 2. 2020-06-19. PMID:30849062. |
dramatic weight loss following addition of aripiprazole to olanzapine in a patient with treatment-resistant schizophrenia: a case report. |
2020-06-19 |
2023-08-13 |
Not clear |
| Andre Soares Santos, Kenya Valeria Micaela de Souza Noronha, Monica Viegas Andrade, Cristina Mariano Rua. Cost-effectiveness and Price of Aripiprazole for Schizophrenia in the Brazilian Public Health System The journal of mental health policy and economics. vol 23. issue 1. 2020-06-04. PMID:32458815. |
cost-effectiveness and price of aripiprazole for schizophrenia in the brazilian public health system schizophrenia is a chronic debilitating condition characterized by disorders in thought, affect and behavior. |
2020-06-04 |
2023-08-13 |
Not clear |
| Meritxell Tost, José Antonio Monreal, Antonio Armario, Juan David Barbero, Jesús Cobo, Clemente García-Rizo, Miquel Bioque, Judith Usall, Elena Huerta-Ramos, Virginia Soria, Javier Laba. Targeting Hormones for Improving Cognition in Major Mood Disorders and Schizophrenia: Thyroid Hormones and Prolactin. Clinical drug investigation. vol 40. issue 1. 2020-06-02. PMID:31612424. |
cabergoline, aripiprazole) are candidate drugs to be tested in repurposing clinical trials aiming to improve the cognitive abilities of patients with major mood disorder and schizophrenia. |
2020-06-02 |
2023-08-13 |
Not clear |
| Jasmina Mallet, Philip Gorwood, Yann Le Strat, Caroline Dubertre. Major Depressive Disorder (MDD) and Schizophrenia- Addressing Unmet Needs With Partial Agonists at the D2 Receptor: A Review. The international journal of neuropsychopharmacology. vol 22. issue 10. 2020-05-19. PMID:31406978. |
the objectives of this review were (1) to discuss the goal of treatment with second-generation antipsychotics in major depressive disorder and schizophrenia, and the clinical factors that should be considered, and (2) to examine the short- and long-term existing data on the efficacy and safety of d2 receptor partial agonists (aripiprazole, cariprazine, and brexpiprazole) in the adjunctive treatment of major depressive disorder and in the treatment of schizophrenia. |
2020-05-19 |
2023-08-13 |
Not clear |
| Daniel Schöttle, Wolfgang Janetzky, Daniel Luedecke, Elmar Beck, Christoph U Correll, Klaus Wiedeman. Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study. BMC psychiatry. vol 18. issue 1. 2020-05-11. PMID:30551736. |
correction to: effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study. |
2020-05-11 |
2023-08-13 |
Not clear |
| Qian Cai, Charmi Patel, Edward Kim, Nancy Connolly, Ozgur Tunceli, Antoine C El Khour. Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study. Advances in therapy. vol 36. issue 4. 2020-05-01. PMID:30848442. |
factors associated with the initiation of long-acting injectable paliperidone palmitate versus aripiprazole among medicaid patients with schizophrenia: an observational study. |
2020-05-01 |
2023-08-13 |
Not clear |
| Qian Cai, Charmi Patel, Edward Kim, Nancy Connolly, Ozgur Tunceli, Antoine C El Khour. Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study. Advances in therapy. vol 36. issue 4. 2020-05-01. PMID:30848442. |
this study investigated variables associated with initiation of treatment with the long-acting injectables paliperidone palmitate (lai-pp) and aripiprazole lai (lai-ap) in medicaid patients with schizophrenia. |
2020-05-01 |
2023-08-13 |
Not clear |
| b' Marta Hereta, Kinga Kami\\xc5\\x84ska, Zofia Rog\\xc3\\xb3\\xc5\\xb. Co-treatment with antidepressants and aripiprazole reversed the MK-801-induced some negative symptoms of schizophrenia in rats. Pharmacological reports : PR. vol 71. issue 5. 2020-04-30. PMID:31351318.' |
co-treatment with antidepressants and aripiprazole reversed the mk-801-induced some negative symptoms of schizophrenia in rats. |
2020-04-30 |
2023-08-13 |
rat |
| Yoshiaki Obayashi, Satoshi Mitsui, Shinji Sakamoto, Nozomu Minao, Bunta Yoshimura, Toshiki Kono, Yuji Yada, Yuko Okahisa, Soshi Takao, Yoshiki Kishi, Toshihiko Takeda, Manabu Takaki, Norihito Yamad. Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole. Psychopharmacology. vol 237. issue 1. 2020-04-10. PMID:31624859. |
we investigated switching methods and related factors for successful switching patients with chronic schizophrenia to aripiprazole. |
2020-04-10 |
2023-08-13 |
Not clear |